2020 Confirmed Speakers
Phil Chamberlain
Eric Fischer
Alessio Ciulli
Gwenn Hansen
Why Attend
“Targeted protein degradation promises to be the greatest innovation in small molecule drug discovery in the new millennium.” - Manfred Koegl, Lab Head Oncology Research, Boehringer Ingelheim
With capital investment coming in fast, industry is ready to commercialise the therapeutic potential of PROTACs and molecular glues to build safe, effective targeted protein degradation products. As Arvinas conducts the groundbreaking first PROTAC clinical trials this year, it could be only be a matter of time before PROTACs and molecular glues enter the market.
The European Protein Degradation Congress will bring together leading industry players within big pharma and biotech along with expert academics in the ubiquitin space - providing an open forum and facilitate the sharing of in vitro and in vivo data, as well as build a deeper mechanistic understanding of the ubiquitin pathways and techniques to make the ‘undruggable’ druggable.
Expect to hear strategies to overcome the structural biology, pharmacology and chemistry obstacles associated with the discovery and development of these bi-functional and single entity molecules.
Previous Attendees Include
highlights from 2019
Talk to our speakers about...
1. How to exploit protein homeostasis to identify new proteins for degradation
2. How to find new E3 ligase recruiters
3. What does the next generation of targeted protein degradation products look like?
4. How can chemo-proteomics be used to make the ‘undruggable’ druggable?
5. Structural-based design of PROTAC through crystallography techniques
6. Furthering our understanding of the ubiquitin space.
7. New synthetic molecular glue approaches from auxin scaffolds
8. How mechanistic understanding of the DUBs space is applicable to targeted protein degradation
9. How well do PROTACs work in clinical application – insights into the first human trial
10. Key medicinal chemical considerations for moving from a PROTAC/molecular glue probe to drug
Audience Breakdown
What attendees say
Previous Speakers
Craig Crews
Dr. Crews is the Lewis Cullman Professor of Molecular, Cellular and Developmental Biology and holds joint appointments in the departments of Chemistry and Pharmacology at Yale University. He graduated from the U. Virginia with a B.A. in Chemistry and received his Ph.D. from Harvard University in Biochemistry. Dr. Crews has a foothold in both the academic and biotech arenas; on the faculty at Yale since 1995, his laboratory pioneered the use of small molecules to control intracellular protein levels. In 2003, he co-founded Proteolix, whose proteasome inhibitor, Kyprolis™ received FDA approval for the treatment of multiple myeloma. Since Proteolix’s purchase by Onyx Pharmaceuticals in 2009, Dr. Crews has focused on a new ‘induced protein degradation’ drug development technology, PROTACs, which served as the founding IP for his latest New Haven-based biotech venture, Arvinas, Inc. From 2008 to 2018, Dr. Crews served an Editor of Cell Chemical Biology and he currently serves on several editorial boards. In addition, he has received numerous awards and honors, including the CURE Entrepreneur of the Year Award (2013), Ehrlich Award for Medicinal Chemistry (2014), Yale Cancer Center Translational Research Prize (2015), a NIH R35 Outstanding Investigator Award (2015), the AACR Award for Outstanding Achievement in Chemistry in Cancer Research (2017), the Khorana Prize from the Royal Society of Chemistry( 2018), the Pierre Fabre Award for Therapeutic Innovation (2018), the Pharmacia-ASPET Award for Experimental Therapeutics (2019) and was named an American Cancer Society Professor in 2018.
Eric Fischer
Eric Fischer, Ph.D. is Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and a Principal Investigator in the Department of Cancer Biology at Dana-Farber Cancer Institute. His research focuses on understanding the complex mechanisms that underlie function and regulation of multi-component ubiquitin ligases and their role in disease. His work further focuses on new therapeutic approaches such as targeted protein degradation. He co-directs the DFCI Center for Protein Degradation and has been recognized for his pioneering work on the structure of cereblon and the mechanism of action of thalidomide.
Gwenn Hansen
Gwenn is Vice President of Drug Discovery Technologies at Nurix Therapeutics, a company focused on discovering and developing next-generation therapies that target protein homeostasis through modulation of the ubiquitin proteasome system. Since joining Nurix in January of 2016, Gwenn has focused on establishing the company’s DNA encoded library technology platform for small molecule discovery, and now leads teams of scientists in both early discovery as well as medicinal chemistry. Prior to joining Nurix, Gwenn spent one year as an Associate Professor in the Center for Drug Discovery at Baylor College of Medicine and over 13 years in a variety of discovery-focused roles at Lexicon Pharmaceuticals, both located in Houston, Texas. Gwenn received her PhD in Biomedical Sciences from Oak Ridge National Laboratory in 1998 and completed postdoctoral training at MD Anderson Cancer Center.
Nicolas Thomä
My laboratory has set out to combine structural biology, cell biology and complex biochemical in vitro reconstitutions to address the molecular workings of these chromatin-bound complex assemblies. Our focus is on machines that detect and repair mutations in the DNA, and those that make possible the accurate passage of epigenetic information to the daughter generation.
Sara Buhrlage
Sara Buhrlage, PhD, is an Assistant Professor in Dana-Farber’s Cancer Biology Department and Harvard Medical School’s Biological Chemistry and Molecular Pharmacology Department. Her research group focuses on the development of first-in-class inhibitors and prototype drugs for deubiquitylating enzymes (DUBs) that can be utilized to pharmacologically validate members of the gene family as new targets for cancer treatment and other diseases. DUBs have garnered significant attention recently as potential therapeutic targets in the field of oncology due to their removal of degradative ubiquitin marks from cancer causing proteins.
Prior to joining as a faculty member in July 2015, Dr. Buhrlage was a professional track scientist at Dana-Farber in the medicinal chemistry core laboratory. In this role she collaborated with Institute researchers to pharmacologically validate novel targets of disease and study mechanisms of oncogenesis and drug resistance.
Dr. Buhrlage completed a Doctor of Philosophy in organic chemistry in 2008, under the direction of Professor Anna Mapp, PhD, from the University of Michigan, where she successfully designed, synthesized and characterized small molecules that bind the transcriptional co-activator CBP and upregulate transcription when tethered to DNA. Following completion of her Doctor of Philosophy, Dr. Buhrlage trained for two years in medicinal chemistry at the Broad Institute.
Manfred Koegl
I am a director in Oncology Research at Boehringer Ingelheim in Vienna, working on the discovery and implementation of new therapeutic concepts in cancer. The main focus of my team are novel approaches for cancer cell targeting by small molecule drugs.
Adam Gilbert
My group supports several important medchem platforms for Pfizer: protein degradation, DNA-encoded library chemistry, large and small-scale compound purification and phenotypic screening deconvolution. Scientists in my group specialize in design and synthetic medicinal chemistry, computational chemistry, purification science as well as molecular property analysis.
Pearlie Epling-Burnette
I am a Senior Member and Professor at the Moffitt Cancer Center & Research Institute, Tampa, FL. As a member of the Immunology Program, I have made several leading observations on immune deregulations in the setting of bone marrow failure, hematological malignancies, and solid tumors. In addition to collaborations with physician scientist to assist with investigator-initiated clinical trials, I have conducted research studies with collaborators focused on Cancer Prevention and Control to uncover the epidemiology of cancer. My research focuses on drug discovery for the design of new therapeutics, and pathology to improve diagnostic testing for personalized treatment matching. My laboratory research efforts are focused on understanding how to potentiate anti-tumor cytotoxic T cells that have the potential to eliminate tumors. Specifically, I have been evaluating the ability of a class of immunomodulatory drugs (IMiDs) to activate anti-tumor cytotoxic T cells in patients with myelodysplastic syndromes and other cancers. This research as led to the discovery that cereblon (an E3-ubiquitin ligase substrate receptor) is involved in blocking anti-tumor T cell activation. The ultimate goal is to realize the potential of immunotherapy for patients with hematologic malignancies and other forms of cancer.
Success in the lab builds excitement, but always leads to more questions. I feel that research it is a never-ending quest for truth. I first received my Doctorate in Pharmacy before obtaining a PhD. I think this stimulated my interest in drug discovery research. After 25 tireless years of research in the field of immunology, I think we are finally hitting our stride.
Marjeta Urh
My role as Director in R&D at Promega is to develop novel technologies and research tools for analysis of nucleic acids and protein function. The breadth of technologies developed in my group span mass spectrometry, novel immunoassays, analysis of protein-protein and protein-small molecule interactions and targeted protein degradation. In addition, my group is involved in developing applications of Promega core technologies such as HaloTag, NanoBRET, NanoBiT and HiBiT technologies.
Dr Jason Brown
Jason co-founded Ubiquigent in 2009 in collaboration with the University of Dundee, the Medical Research Council and a US biotech. Ubiquigent’s mission is to support and enable client ubiquitin system targeted drug discovery through the identification and characterisation of novel compounds across multiple therapeutic areas. The company is a provider of such collaborations and services worldwide to both commercial pharmaceutical and biotechnology companies as well as academic groups. Before starting Ubiquigent he was part of a biotech investment and operations group and involved in supporting molecular diagnostics, kinase drug discovery and various other drug discovery-focused service companies, along with evaluating investment opportunities. Prior to this he built and ran a kinase-focused assay development and drug discovery service facility for Upstate Biotechnology, a leading provider of cell signalling research products and services. Jason received his MPhil and DPhil from the University of Cambridge in association with Parke-Davis/Warner-Lambert (Pfizer), during which he identified a voltage-dependent calcium channel subunit as the novel molecular target of the blockbuster epilepsy and neuropathic pain drugs Neurontin and Lyrica. After his DPhil Jason worked in and subsequently ran an assay development group for Parke-Davis.
Daniel Nomura
Dan Nomura is an associate professor in the Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology at the University of California, Berkeley. He is also an associate adjunct professor in the Department of Pharmaceutical Chemistry at UCSF. He is also the director of the Novartis-Berkeley Center for Proteomics and Chemistry Technologies. Dr. Nomura is also an editor for Cell Chemical Biology and Current Protocols in Chemical Biology. He earned his B.A. in Molecular and Cell Biology and Ph.D. in Molecular Toxicology with Professor John Casida at UC Berkeley and was a postdoctoral fellow at The Scripps Research Institute in chemical physiology with Professor Ben Cravatt before returning to UC Berkeley as a faculty member in 2011. Among his honors are selection as a Searle Scholar, American Cancer Society Research Scholar Award, the Department of Defense Breakthroughs Award, and the Mark Foundation for Cancer Research INSPIRE award. Research in the Nomura Research Group is focused on reimagining druggability using chemoproteomic platforms to discover new disease therapies.
Claudio Joazeiro
Broadly we are interested in the E3 ubiquitin ligases –their biological functions, mechanism of action, and roles in disease. For the past few years, we have focused on the problem of how cells know when its proteins are aberrant or damaged, and then decide on ways to either correct or eliminate them. Protein quality control is critical to ensure proteome integrity and cellular fitness; further underscoring its relevance, defective protein quality control is a hallmark of neurodegenerative diseases.
In eukaryotic organisms, key factors conferring specificity to protein quality control are molecular chaperones and E3 ligases. We have recently discovered a novel protein quality control mechanism mediated by an E3 ligase, Listerin/Ltn1, and which takes place on ribosomes. We now know that Listerin functions as a subunit of the Ribosome-Associated Quality Control (RQC) complex, which is conserved from yeast to humans. Of relevance, Listerin mutation causes motor neuron degeneration in mice.
We employ diverse model systems and approaches to elucidate how RQC-mediated quality control occurs at the cellular and molecular levels, including biochemistry, yeast genetics, cell biology, mouse models of neurodegeneration, and structural biology. We also analyze patients’ genomes to identify mutations that affect protein quality control; these studies are leading to insights onto the molecular basis of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases, and to potential therapeutic targets.
In addition to the projects on Listerin, we have been working to elucidate the functions and mechanisms of the mitochondria-anchored E3 ligase, MULAN/MUL1, and to develop small molecule inhibitors of E3 ligases that can be used as oncology therapeutics.
James Hunt
James Hunt is an Associate Director in the Discovery Biology department of Discovery Sciences, which is part of the AstraZeneca IMED Biotech Unit. James leads the Affinity Reagents team, who have global responsibility for delivering antibodies and other affinity reagents for use as research tools to AstraZeneca’s Innovative Medicines and Early Development drug discovery programmes.
Nan Ji
Nan Ji, Ph.D., is Executive Director and Head of Chemistry at Kymera Therapeutics. Nan has more than 10 years of drug discovery experience. Before Kymera, he spent 2 years at Mitobridge (now part of Astellas), where he was responsible for its NAD+-boosting portfolio with multiple approaches to modulate mitochondrial functions. Prior to that, Nan spent 7+ years at Novartis, where he contributed to and delivered multiple clinical and preclinical development candidates. Nan obtained his Ph.D. in Organic Chemistry with Prof. Andy Myers and conducted his postdoc with Prof. Eric Jacobsen at Harvard University.
Anil Vasudevan
Seth Margolis
Dr. Margolis received his Bachelor of Science in Biochemistry at the University of Rochester (Rochester, NY). In 1999, he joined graduate school at Duke University Medical Center (Durham, North Carolina) in the department of Pharmacology and Cancer Biology. There, Dr. Margolis completed a doctoral thesis with Dr. Sally Kornbluth focusing on molecular mechanisms of DNA-responsive cell cycle checkpoints using the frog Xenopus egg extract system. Following completion of a Ph.D., in 2006 Dr. Margolis joined the laboratory of Dr. Michael Greenberg in the department of Neurobiology at Harvard University (Boston, Massachusetts). During a postdoctoral tenure with the guidance and support of Dr. Greenberg, Dr. Margolis focused his efforts on the molecular pathways that regulate excitatory synapse formation and investigating their relevance to the pathophysiology of the cognitive disorder Angelman Syndrome. In September 2011, Dr. Margolis joined the Department of Biological Chemistry at the Johns Hopkins University School of Medicine as an Assistant Professor. The vast majority of Dr. Margolis work is centered on understanding how molecular mechanisms that restrict synapses during development are reactivated in neurodevelopmental and neurodegenerative disease. To this end, Dr. Margolis and his group use genetically engineered mouse models of disease and a multidisciplinary approach that combines aspect of molecular biology, biochemistry and in vivo synapse imaging in order to develop hypothesis about the underlying cause of synapse degeneration and cognitive decline. They then use genetic rescue or stereotactic approaches to target distinct pathways followed by a wide range of behavioral tasks to assay cognitive function and tests their hypotheses. More recently, Dr. Margolis has developed a new direction focused on cellular protein homeostasis mechanisms related to protein degradation and their impact on changes in the function and physiology of the nervous system. Using a wide range of classic biochemical purification approaches, Dr. Margolis and his team have identified novel proteasome mediated pathways in the nervous system and are just beginning to understand their relevance to health and disease.
Rajesh Chopra
Professor Rajesh Chopra is Director of the Cancer Research UK Cancer Therapeutics Unit and Head of the Division of Cancer Therapeutics at the Institute of Cancer Research in London. He has had experience of working both in academia and industry having been Director of Hematological Oncology, Christie Hospital in Manchester and subsequently in the Oncology Therapeutic area at AstraZeneca.
From 2009-2016, he was leader of the Executive R&D Team and Corporate Vice President of Translational and Early Drug Development at Celgene Corporation, Summit, NJ, where he led a team of over 100 scientists in San Diego, San Francisco and Seville. There he was involved in a large number of drug discovery and development projects and part of a team that helped to define the mechanism of action of Thalidomide and its analogues. In addition, Raj was also involved in the New Drug Applications for pomalidomide (a second generation IMiD agent) and apremilast (a PDE4 inhibitor). Both drugs were approved in 2013 and 2014 respectively.
Yusuke Tominari
Yusuke Tominari is a CEO and CEO, and manages the entire projects and strategy of FIMECS, Inc. He curved out from Takeda pharmaceutical company limited with his colleagues and launched FIMECS in 2018. He started his career of medicinal chemist at Takeda in 2006 after getting a PhD at the University of Tokyo in Japan. Through his 12 years of pharmaceutical experience, he has been mainly working on immunology and oncology areas.
FIMECS, Inc. is a drug discovery biotech developing a new class of drugs based on targeted protein degradation therapeutics for currently ‘undruggable’ targets in immune-oncology and oncology areas.
Utilizing our drug discovery platform, RaPPIDSTM to internal and collaborative programs, we rapidly discover therapeutic candidates to induce the degradation of disease-relevant targeted proteins.
Most important mission is the providing life-saving medicines to patients all over the world.
Phil Chamberlain
Phil Chamberlain obtained his BA and D.Phil. degrees from the University of Oxford before traveling to the U.S. to perform his post-doctoral work at the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego. Phil joined Celgene, San Diego in 2007 and leads the Structural and Chemical Biology department which provides structural, biochemical and cellular data in support of drug discovery projects. Phil is known for his work in understanding and extending the action of cereblon modulators, and has published work in this area in journals including Nature and Nature Structural and Molecular Biology.
Keith Hornberger
Keith Hornberger is Director of Chemistry at Arvinas, Inc., where he leads the medicinal chemistry team supporting the discovery of PROTAC™ targeted protein degraders for oncology. Prior to joining Arvinas in 2016, Keith held multiple positions in preclinical drug discovery at GlaxoSmithKline, OSI Pharmaceuticals (a subsidiary of Astellas), and Boehringer Ingelheim over a span of 14 years. Keith completed his Ph.D. in organic chemistry at Columbia University in 2002.
Anne Bertolotti
Anne obtained her Ph.D. from Strasbourg University (France), and did a post doc at The Skirball Institute of Biomolecular Medicine, NYU, New York. She has been a group leader at the MRC Laboratory of Molecular Biology since 2006. She was an INSERM Investigator from 2000 to 2006, was elected an EMBO Young Investigator in 2005, was awarded an ERC consolidator grant in 2013, became and EMBO member in 2013 and won the Hooke Medal in 2014. In 2017, she became a Fellow of the National Academy of Medical Sciences in the UK and was awarded a Wellcome Trust Investigator Award. In 2018, she won the GlaxoSmithKline Award from the Biochemical Society.
Anne has made seminal contributions to our current understanding of protein quality control mechanisms in cells, which represent the cellular defence systems against potentially harmful proteins. She was one of the pioneer in the discovery of mammalian unfolded protein response and more recently discovered the pathways by which cells maintain proteasome homeostasis.
She has also identified mechanisms underlying the deposition of misfolded proteins in neurodegenerative diseases and contributed to a dogmatic shift in this field with the discovery that mutant SOD1 aggregates propagate indefinitely just like prions.
With the knowledge acquired on protein quality control systems, Anne identified strategies to boost their function and is currently exploiting them for the treatment of neurodegenerative diseases. One of the strategy consists in selective inhibition of a phosphatase, an important advance because phosphatases were thought to be undruggable.
Gold Partner
Promega
Website: https://www.promega.com
Promega Corporation is a world leader in providing innovative solutions to the life sciences. We develop bioluminescent technologies that deliver more biologically relevant data for small and large molecule drug discovery. We are the commercial leader in offering sensitive, real-time assays for PROTACs and Protein Degradation. Is my target protein degraded? Is it recruited to the proteasome? Is my PROTAC cell permeable? Speak with a Promega representative to learn how to answer these questions. For more information www.promega.com.
Silver Partner
Proteome Sciences
Website: https://www.proteomics.com/
Proteome Sciences is a Contract Research Organisation (CRO) specialising in the analysis of proteins detected by Mass Spectrometry. We offer various Discovery and Targeted Services to characterise proteins and their associated post translational modifications.
By using LC-MS2, LC-MS3, SysQuant® and TMTcalibratorTM methodologies on samples that originate from tissue to biological fluids, we can detect over 8,000 proteins per sample. With our proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated in either disease progression or drug treatment.
Using our unique TMTpro isobaric mass tags, we can run up to 15 samples per single experiment thereby allowing relative protein quantification between samples. By using a reference channel, multiple experiments can be performed sequentially, thereby allowing 30 to 100+ samples to be characterized in one project. Sensitivity is equivalent to conventional ELISA in many cases.
In the clinical area, we offer single or multiplexed protein measurements on customer selected proteins either with or without a PTM. Proteins selected can be either known previously, or more often detected above via our Discovery Services. We can measure up to 100 multiplex proteins per sample in a GCLP accredited Targeted Mass Spectrometric assay using clinically relevant samples such as plasma and CSF. Again, sensitivity is equivalent to conventional ELISA in many cases.
Previous Partners
Bio- Techne
Website: https://www.bio-techne.com/
The Bio-Techne family of brands offer a unique portfolio of high-quality reagents, instruments and services for life science researchers. To enable scientists working in the rapidly growing field of Targeted Protein Degradation, Bio-Techne provides a bespoke range of tools and reagents for the discovery, development and application of Degraders as well as custom services.
- Active Degraders and Degrader Building Blocks: The Tocris brand has pioneered commercialization of tool Degraders to make them available to the research community for investigating the phenotypic consequences of targeted protein knockdown. Tocris also supplies chemical building blocks (functionalized E3 ligase ligands plus linkers) to enable researchers to generate their own Degraders and offers custom synthesis of bespoke panels of Degrader Building Blocks.
- Ubiquitin Proteasome System (UPS) Proteins and Assays: Boston Biochem is the leading global provider of UPS related research products, with a catalog that includes UPS proteins, related antibodies and assay kits, as well as custom expertise in protein purification, characterization, modification, and assay development.
- Assays for Protein Degradation: Simple WesternTM systems from ProteinSimple, such as Wes™ and Jess, simplify and accelerate the detection of Degrader-mediated protein knockdown by automating the entire protein separation and detection process.
Ubiquigent
Website: https://www.ubiquigent.com/
Ubiquigent is a unique collaboration partner in ubiquitin-system based protein degradation drug discovery.
We have developed and make available to our partners a comprehensive assay and medicinal chemistry platform enabling the design, characterisation and development of deubiquitylase (DUB) targeted small molecule inhibitors. DUBs represent a family of almost 100 enzymes that regulate targeted protein degradation, providing a rich seam of novel drug target opportunities addressing a number of therapeutic areas including oncology, neurodegeneration and fibrosis.
Ubiquigent also has a strong capability in developing and running compound screening assays to targets across the ubiquitin system, including E3 ligases. Such assays having utility in supporting PROTAC-based drug discovery.
Commercial relationships with Ubiquigent may be both on a CRO or an exclusive Collaborative Drug Discovery basis. In the latter case Ubiquigent can provide exclusivity around both the target and our novel chemistry. Ubiquigent is target and therapeutic area agnostic working with a range of companies and groups. Partners range from those with significant expertise and activity in the ubiquitin and protein degradation field to those with little experience in the area. Typically partners bring strong therapeutic area expertise and Ubiquigent the ubiquitin and protein degradation drug discovery capabilities.
NanoTemper
Website: https://nanotempertech.com/
NanoTemper Technologies is deeply committed to the best customer experience. Central to this is a strong focus on enabling researchers to easily, efficiently, and accurately perform protein characterization. With a broad offering of systems, software and consumables for evaluating binding affinities and protein stability, scientists in pharmaceutical, biotech or academic labs will find an optimized workflow, quality results and responsive customer support. Work with a deeply experienced and globally operating team, and realize the NanoTemper experience.
Pfizer
Website: https://www.pfizer.com/
Pfizer is one of the world's premier innovative biopharmaceutical companies, discovering, developing and providing over 160 different medicines, vaccines and consumer healthcare products to help improve the lives of millions of people around the world every year. Our purpose is grounded in our belief that all people deserve to live healthy lives. This drives our desire to provide medicines that are safe and effective.
Media Partners
RxNet
Website: https://www.rx-network.com
RxNet is a free online community, uniting scientists from the fields of chemistry, biochemistry and beyond to further the ever-booming industry of drug discovery and development.
We aim to provide current and existing research and information on all aspects of the drug discovery pipeline through publishing a range of exclusive content including the latest news, up-to-date research, expert interviews and peer-reviewed journal articles.
RxNet members can connect and collaborate with industry leaders and academic experts as well as share their own research and opinion without the wait.
The Agenda
We are still finalisng the agenda for the Europe 2020 congress. Please download the example agenda from our Europe 2019 Congress to get a feel for the topics of discussion.
What you can expect from the 2020 congress:
- 200+ participants from leading industry players within big pharma and biotech along with expert academics in the ubiquitin space.
- An open forum to share the latest in vivo and in vitro data and insights and foster collaboration.
- 18+ thought leaders on the speaking agenda and ready to answer your big questions on overcoming translational hurdles.
- 2 days of progressing translation of protein degradation probes into safe, effective therapeutics.
Download Previous Agenda
Become a Sponsor
Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.